Unicycive Therapeutics to Participate in Upcoming Investor Events in December
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December.
Event: Piper Sandler 37th Annual Healthcare Conference
Type: Fireside chat
Date/Time: Wednesday, December 3, 2025, at 10:00 a.m. ET
Event: Noble Capital Markets Virtual Presentation
Date/Time: Wednesday, December 10, 2025, at 10:00 a.m. PT
A link to the live and archived Piper Sandler webcast, as well as an archived link of the Noble presentation, may be accessed on the Unicycive website under the Investors section: . To schedule a 1x1 meeting with management, please contact your Piper Sandler conference representative.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit and follow us on and .
Investor Contact:
Kevin Gardner
LifeSci Advisors
Media Contact:
Layne Litsinger
Real Chemistry
SOURCE: Unicycive Therapeutics, Inc.
